Evidence map›Paper›PMID 41168466›Full record

ArticleScientific reports2025

Uncovering potent natural phytochemicals targeting SARS-COV-2 spike protein variants: molecular dynamics insights.

Tuba Sevimoglu, Elif Kızılpınar, Zihni Onur Çalışkaner, İrem Nur Zengin

Abstract read
In one paragraph

Article in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Tuba SevimogluDepartment of Bioengineering, University of Health Sciences, 34668, Istanbul, Turkey. tuba.sevimoglu@sbu.edu.tr.ORCID http://orcid.org/0000-0003-4563-3154
Elif KızılpınarDepartment of Neuroscience, Uskudar University, 34662, Istanbul, Turkey.
Zihni Onur ÇalışkanerDepartment of Molecular Biology and Genetics, Biruni University, 34015, Istanbul, Turkey.
İrem Nur ZenginDepartment of Chemistry, Gebze Technical University, 41400, Kocaeli, Turkey.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

SARS-CoV-2 remains a critical global health concern due to its high transmissibility, evolving variants, and the absence of a universally effective treatment. Phytocompounds, known for their antiviral, anti-inflammatory, and immunomodulatory properties, continue to be explored as potential therapeutic agents. This study evaluated 20 phytocompounds and four approved antiviral drugs, Remdesivir, Favipiravir, Hydroxychloroquine, and Ivermectin, against nine SARS-CoV-2 spike glycoprotein structures, including five wild-type and four variants (Alpha, Beta, Delta, and Omicron). Molecular docking using two software platforms identified ursolic acid, betulinic acid, β-sitosterol, and ivermectin as top candidates, with binding affinities ranging from - 6.7 to - 9.6 kcal/mol. These compounds also displayed favorable pharmacokinetic properties and druggability. 100 ns molecular dynamics simulations were performed on the highest-affinity complexes to assess stability. Betulinic acid and β-sitosterol demonstrated stable binding interactions, with low RMSD values (~ 0.2-0.3 nm) and consistent hydrogen bonding (1-3 bonds), suggesting structural stability. In contrast, ursolic acid and ivermectin showed unstable binding and higher structural fluctuations during simulation. Overall, the study highlights betulinic acid and β-sitosterol as presumptive SARS-CoV-2 inhibitors, warranting further experimental validation through in vitro and in vivo studies to confirm their therapeutic potential.

Indexed as

Antiviral AgentsCOVID-19 Drug TreatmentPhytochemicalsSARS-CoV-2Spike Glycoprotein, CoronavirusAdenosine MonophosphateAlanineAmidesBetulinic AcidCOVID-19HumansIvermectinMolecular Docking SimulationMolecular Dynamics SimulationPentacyclic TriterpenesProtein BindingAdenosine MonophosphateAlanineAmidesAntiviral AgentsBetulinic Acidfavipiravirgamma-sitosterolIvermectinPentacyclic TriterpenesPhytochemicalsPyrazinesremdesivirSitosterolsSpike Glycoprotein, Coronavirusspike protein, SARS-CoV-2TriterpenesUrsolic AcidAntiviralMolecular dynamics simulationsPhytocompoundsSars-CoV-2Spike glycoprotein

Identifiers

PMID41168466
PMCPMC12575622

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.